AC Immune SA
Clinical trials sponsored by AC Immune SA, explained in plain language.
Biotech developing immunotherapies for neurodegenerative diseases like Alzheimer's.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new PET tracer light up the protein behind some dementias and ALS? Results expected Nov 2026 (estimated)
- New brain drug ACI-19764 enters first human safety tests Results expected Dec 2026 (estimated)
-
Experimental Alzheimer's vaccine aims to clear brain plaques
Disease control Recruiting nowThis study tests an experimental vaccine called ACI-24.060 in people with early Alzheimer's and non-demented adults with Down syndrome. The vaccine is designed to help the immune system clear amyloid plaques from the brain, which are linked to Alzheimer's. Researchers will check …
Phase 1/2 • Sponsor: AC Immune SA • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Can a new PET tracer light up the protein behind some dementias and ALS?
Diagnosis Recruiting nowThis early-phase trial is testing whether an experimental imaging agent called [18F]ACI-19626 can safely and reliably detect abnormal clumps of a protein called TDP-43 in the brain using PET scans. TDP-43 buildup is linked to certain forms of dementia, such as frontotemporal deme…
Early phase 1 • Sponsor: AC Immune SA • Aim: Diagnosis
Last updated Aug 28, 2026 00:00 UTC
-
New PET tracer aims to spot Parkinson's protein in the brain
Diagnosis Recruiting nowThis early-phase study tests a new radioactive tracer called [18F]ACI-15916, designed to detect clumps of α-synuclein protein in the brain using PET scans. These protein deposits are linked to Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies. The trial …
Early phase 1 • Sponsor: AC Immune SA • Aim: Diagnosis
Last updated Jun 27, 2026 07:58 UTC
-
New brain drug ACI-19764 enters first human safety tests
Knowledge-focused Recruiting nowThis early-stage trial is testing a new drug called ACI-19764 in 78 healthy adults to see if it is safe and how the body handles it. The drug targets a protein in the brain linked to inflammation. Participants will receive either the drug or a placebo, and researchers will monito…
Phase 1 • Sponsor: AC Immune SA • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC